Gilead

We're entering 2025 with momentum and strength. As the long-standing leader in HIV, we’re committed to helping end the epidemic with the advancement of unprecedented long-acting medications for both HIV prevention and treatment. Our diversified pipeline has the potential to deliver best-in-class therapies to address multiple myeloma and other types of cancer, the rare liver disease primary biliary cholangitis, and other diseases across our therapeutic areas.

https://www.gilead.com/